Cargando…
Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
BACKGROUND: Symptoms are common among patients enrolled in phase I trials. We assessed the validity of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in relation to previously validated assessments of quality of life and psychological distre...
Autores principales: | Sedhom, Ramy, Ferrell, Betty, Ruel, Nora, Koczywas, Marianna, Chung, Vincent, Smith, Thomas J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768928/ https://www.ncbi.nlm.nih.gov/pubmed/33392443 http://dx.doi.org/10.1093/jncics/pkaa067 |
Ejemplares similares
-
Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients
por: Chung, Vincent, et al.
Publicado: (2022) -
Cancer Communication and Family Caregiver Quality of Life
por: Wittenberg, Elaine, et al.
Publicado: (2017) -
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology
por: Douma, Joeri A. J., et al.
Publicado: (2021) -
Mini-review of kidney disease following hematopoietic stem cell transplant
por: Sedhom, Ramy, et al.
Publicado: (2018) -
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
por: Reckamp, Karen L., et al.
Publicado: (2019)